CD79A and myeloid sarcoma: We have discovered that compared with non‐MS controls, BLNK protein levels in people with MS are significantly lower in all circulating B cells analyzed, particularly the IgA+, IgG1+ and IgG2+ subsets we have identified to play a novel role in MS pathogenesis and their response to alemtuzumab.